Hypomethylating agents (HMAs) do not appear to play a role in the development of Clostridium difficile infection (CDI) in patients with myelodysplastic syndrome or acute myeloid leukemia, according to a study involving 223 individuals. Participants—all of whom had either MDS or AML—were hospitalized at a single center over a ~2-year period ending in 2013. Investigators compared those with and without CDI to determine predictors of the disease. Among the results:
- 15% developed CDI.
- Albumin at time of hospitalization, prior diagnosis of CDI, receipt of cytarabine-based chemotherapy, and total days of hospitalization were significantly linked with CDI.
- Receipt of DNA HMA-based chemotherapy, gender, proton-pump inhibitor use, and receipt of antibiotics were not linked with such.
Shah K, Curtin B, Chu C, Hwang D, Flasar M, von Rosenvinge E. Characteristics of Clostridium difficile infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemia. World J Clin Oncol. 2017;8(5):398-404. doi:10.5306/wjco.v8.i5.398.
This Week's Must Reads
Must Reads in AML
Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al
Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al
Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al
Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al
Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al